kappa-Opioid receptor stimulation inhibits augmentation of Ca(2+) transient and hypertrophy induced by isoprenaline in neonatal rat ventricular myocytes - Role of CaMKIIdelta(B)

European Journal of Pharmacology
Guoqiang WuTak Ming Wong

Abstract

We aimed to further define the pathway mediating the inhibitory effects of kappa-opioid receptor stimulation on Ca(2+) transients and hypertrophic responses to beta(1)-adrenoceptor stimulation. We determined the effects of trans-(+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]-benzeneacetamid methanesulfonate salt (U50,488H), a selective kappa-opioid receptor agonist, on the enhancement of spontaneous Ca(2+) transients and the induction of hypertrophy by isoprenaline, a beta-adrenoceptor agonist, in cultured neonatal ventricular myocytes. The results were compared with those found with KN93, a selective Ca(2+)/calmodulin-dependent kinase (CaMKII) inhibitor, propranolol, a beta-adrenoceptor antagonist, and verapamil, a L-type Ca(2+) channel antagonist. Hypertrophy of cardiomyocytes was characterized by increases in (i) total protein content; (ii) cell size; and (iii) [(3)H]leucine incorporation. 10 micromol/l isoprenaline increased all three parameters. We also determined the expression of nuclear CaMKIIdelta in response to U50,488H in the presence or absence of isoprenaline. To determine whether the effects of U50,488H were receptor-mediated, its effects were also measured following blockade of the kappa-opioid rec...Continue Reading

References

Jun 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·R S ZukinA Tempel
Jan 1, 1995·Advances in Second Messenger and Phosphoprotein Research·D L Campbell, H C Strauss
Aug 3, 2001·Journal of Cardiovascular Pharmacology·X C YuT M Wong
Apr 27, 2002·Pflügers Archiv : European journal of physiology·Jian ShanTak-Ming Wong
Jul 3, 2003·Nature Reviews. Molecular Cell Biology·David H MacLennan, Evangelia G Kranias
Nov 18, 2003·The Journal of Physiology·Min WangJoshua R Berlin
Mar 6, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Amjid A RiazHenrik Thorlacius
Sep 15, 2004·European Journal of Pharmacology·Guijun WangTak Ming Wong
Feb 28, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Carmen C SucharovMichael R Bristow
Apr 3, 2007·Journal of Molecular and Cellular Cardiology·Norbert NagyDipak K Das

❮ Previous
Next ❯

Citations

Dec 19, 2014·British Journal of Pharmacology·John P HeadrickJason N Peart
Oct 5, 2010·Critical Care Medicine·Quan-Yu ZhangJian-Ming Pei
Mar 13, 2018·Journal of Cardiovascular Pharmacology and Therapeutics·Hemangi Rawal, Bhoomika M Patel
Feb 24, 2009·European Journal of Pharmacology·Wen YinJian Ming Pei
Oct 2, 2009·Peptides·Richard J Bodnar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.